Here is an overview of important key figures for the MEB. This is not a complete reflection of all activities of the MEB.
Medicinal products for human use and marketing authorisation
New applications and authorisations
| 27 | Medicinal products with a new active substance |
| 457 | Dutch DCP RMS procedures |
| 1.205 | New marketing authorisations (including parallel) |
| 12.810 | Variations in existing medicinal product authorisations |
| 14.011 | Total number of authorised medicinal products |
European representation
| 101 | Netherlands involved as Scientific Advice coordinator (SAWP) |
| 23 | Netherlands Paediatric Investigation Plan Rapporteur (PDCO) |
| 21 | Netherlands Rapporteur authorising orphan drug status (COMP) |
| 18 | Netherlands CHMP rapporteur or co-rapporteur |
| 13 | Netherlands involved as PRAC rapporteur |
Veterinary medicinal products
New applications and authorisations
| 6 | Medicinal products with a new active substance |
| 15 | Applications DCP RMS procedures |
| 115 | New national marketing authorisation |
| 2.620 | Total number of authorised veterinary medicinal products |
European representation
| 10 | Netherlands (co-)rapporteur CVMP |
| 2 | Netherlands (co-)rapporteur new Maximum Residue Limits |
Botanicals and novel foods
| 2 | DCP procedures herbal medicinal products on the basis of complete dossier |
| 3 | DCP procedures herbal medicinal products on the basis of traditional use |
| 1 | MRP procedure herbal medicinal products on the basis of complete dossier |
| 48 | Number of authorised herbal medicinal products on the basis of complete dossier |
| 43 | Number of authorised herbal medicinal products on the basis of traditional use |
| 175 | New procedures for botanicals and novel foods |
